Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 2
Diabetes kidney prevention: German model
A German model found semaglutide cost-effective for kidney prevention, while tirzepatide gained more health at a much higher modeled cost.
Food, memory and cravings: Kanoski
Scott Kanoski explains how meal memory and GLP-1 pathways shape appetite, with important limits around rodent sweetener research.
Oral semaglutide for alcohol use disorder
A 50-person randomized trial missed its primary craving endpoint but found signals on heavy drinking days and other secondary measures.
Oral semaglutide and arterial stiffness
A retrospective cohort linked higher-dose oral semaglutide and SGLT-2 inhibitor use with improved arterial stiffness, without proving causation.
PCSK1 Obesity: Two GLP-1 Cases
Two sisters with a loss-of-function PCSK1 mutation lost 16% to 27% of body weight on GLP-1-based treatment, raising a mechanism question.
Peptides in sexual medicine: evidence
A 2026 review separates approved bremelanotide evidence from early kisspeptin research and unsupported claims for growth hormone peptides.
Semaglutide MASH Cost-Effectiveness Model
A 2026 US payer model projected semaglutide as cost effective for non-cirrhotic MASH, but lifetime results depend on assumptions and sponsor inputs.
Tirzepatide and Pneumatosis Intestinalis
A 2026 case report links tirzepatide exposure with histologically confirmed pneumatosis intestinalis in one patient, without proving general risk.
CagriSema REDEFINE 1 Target Analysis
A post hoc REDEFINE 1 analysis found more CagriSema participants reached BMI and waist-to-height targets, but the cutoffs need prospective validation.
GLP-1 Cardiovascular Umbrella Review
A 2026 umbrella review found stronger cardiovascular evidence in people with established disease, with more limited tirzepatide-specific certainty.
GLP-1 Drugs and NAION: A 2026 Review
A 2026 review found a rare NAION safety signal around GLP-1 medicines, led mainly by observational semaglutide data.
GLP-1 Drugs for Opioid Use Disorder?
A 2026 review traces GLP-1 addiction research from animal studies to early human signals, while completed randomized evidence remains sparse.